# HUTCHMED (China) Ltd (HCM)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/hutchmed-china-ltd/ JSON: https://steadybase.io/company/hutchmed-china-ltd.json Checked Nov 21, 2026. Latest filing read: Mar 5, 2026.

## Company

- Legal name: HUTCHMED (China) Ltd
- Ticker: HCM, HMDCF (Nasdaq, OTC)
- SEC CIK: 0001648257
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Hong Kong
- SEC filer category: Large accelerated filer
- Investor relations: https://www.hutch-med.com/shareholder-information/event-information/
- LinkedIn: https://www.linkedin.com/company/hutchmed

## Key facts

- Revenue: $548.5M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/0001104659-26-023822-index.html
- Operating income: -$39.2M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/0001104659-26-023822-index.html
- Net income: $456.9M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/0001104659-26-023822-index.html
- SG&A: $66.7M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/0001104659-26-023822-index.html
- Shares outstanding: 872,327,620 as of Dec 31, 2025 (20-F filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/0001104659-26-023822-index.html
- Auditor: Pricewaterhousecoopers Zhong Tian LLP, Shenzhen, the People’s Republic of China, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm

## Business

We are a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. Our company started in China in 2000 and has since developed fully integrated capabilities and expanded oncology and immunology drug development operations globally.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $548.5M | -$39.2M | $456.9M | $66.7M |
| Dec 31, 2024 | $630.2M | -$43.7M | $37.7M | $64.3M |
| Dec 31, 2023 | $838.0M | $18.4M | $100.8M | $79.8M |
| Dec 31, 2022 | $426.4M | -$407.7M | -$360.8M | $92.2M |
| Dec 31, 2021 | $356.1M | -$328.3M | -$194.6M | $89.3M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/hutchmed-china-ltd.json

## Officers and directors

- Chig Fung Cheng, Acting CEO and CFO. Source: Form 4 filed May 21, 2026, https://www.sec.gov/Archives/edgar/data/1648257/000110465926064789/0001104659-26-064789-index.htm
- Wei-guo Su, CEO and CSO. Source: Form 4 filed May 21, 2026, https://www.sec.gov/Archives/edgar/data/1648257/000110465926064772/0001104659-26-064772-index.htm
- Lorenso Chiu, Deputy Chief Financial Officer. LinkedIn: https://linkedin.com/in/lorenso-chiu-1b9911ab. Source: Form 4 filed May 21, 2026, https://www.sec.gov/Archives/edgar/data/1648257/000110465926064757/0001104659-26-064757-index.htm
- Charles George Rupert Nixon, Group General Counsel. Source: Form 4 filed May 21, 2026, https://www.sec.gov/Archives/edgar/data/1648257/000110465926064778/0001104659-26-064778-index.htm

## Latest filings

- 20f filed Mar 5, 2026: https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

